Short answer
RxSight, Inc. (RXST) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $30M (down 14.1% year over year) with net income of −$10M.
Q3 2025 key financials · XBRL
- Revenue
- $30M
- −14.1% YoY · −9.8% QoQ
- Net income
- −$10M
- −54.9% YoY · +16.7% QoQ
- Operating margin
- -40.1%
- Gross margin
- 79.9%
- EPS (diluted)
- −$0.24
- −50.0% YoY · +17.2% QoQ
Source: XBRL data from the RxSight, Inc. (RXST) Q3 2025 10-Q on SEC EDGAR. USD.
RxSight, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $30.3M, down 14.1% YoY from $35.3M
- Gross margin 79.9% vs 71.4% YoY; operating loss $12.2M vs $9.2M
- Best line LAL revenue $25.7M, up from $24.2M; worst LDD revenue $3.2M vs $10.1M
- Cash, equivalents and short-term investments $227.5M at September 30, 2025
- Near-term losses and negative operating cash flows expected; liquidity sufficient for at least 12 months
Risk Factors
- Newly added trade-policy risk: recently announced U.S. tariffs could increase costs for China-sourced materials and pressure gross margins
- Most materially updated commercial risk: 2025 sales declined after rapid growth, prompting a unified Customer Success Organization
- Regulatory risk: QSMR replaces QSR in February 2026, requiring compliant manufacturing processes
- Litigation risk: putative securities class action complaint filed July 2025 in Central District of California remains pending
- Liquidity concentration: $227.5 million in cash, equivalents, and short-term investments held with one financial institution as of September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RxSight, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.